MedTrace Logo

Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC)

NCT04990063 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-08-04

No results posted yet for this study

Summary

Innate immune cells are an important part of the body's innate immune system, the first line of defense against infection and cancer. Tumor killer cells (TKC) are mixed cultures of two kinds of innate immune cells, namely natural killer cells (NK cells) and gamma delta T cells (γδT cells), which are co-activated and co-cultured ex-vivo in a certain proportion by the unique TKC technology. Adoptive TKC transfer is expected to exert a strong anti-tumor effect through synergistic action between NK cells and γδT cells. In this study, the safety, tolerance, and preliminary efficacy of adoptive TKC transfer combined with chemotherapy will be examined in patients with advanced NSCLC.

Conditions

Interventions

DRUG

Chemotherapy

Standard chemotherapy drug

BIOLOGICAL

Adoptive TKC transfer therapy

TKC: co-cultured autologous NK cells and γδT cells

Sponsors & Collaborators

  • Shanghai Biomed-union Biotechnology Co., Ltd.

    collaborator UNKNOWN

  • suhaichuan

    lead OTHER

Principal Investigators

  • Helong Zhang · IEC of Institution for National Drug Clinical Trials ,Tangdu Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-08
Primary Completion
2022-08-08
Completion
2023-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04990063 on ClinicalTrials.gov